pyrazines has been researched along with Benign Monoclonal Gammopathies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J | 1 |
| An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D | 1 |
| Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W | 1 |
| Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Aline-Fardin, A; Aucouturier, P; Bender, S; Boffa, JJ; Brahimi, S; Buob, D; Fabiani, B; Garderet, L; Mothy, M; Ronco, P; Verpont, MC | 1 |
| Caron, C; Debliquis, A; Itzhar-Baikian, N; Ojeda-Uribe, M | 1 |
| Bergsagel, PL; Chesi, M; Chng, WJ; Chung, TH; Fonseca, R; Gonzalez-Paz, N; Huang, GF; Mulligan, G; Ng, SB; Troska-Price, T | 1 |
| Iwama, K; Matsue, K; Nishida, Y; Takeuchi, M; Yamakura, M | 1 |
| Ahles, CP; Berenson, JR; Boccia, R; Bonavida, B; Chen, H; Crowley, J; Dreyer, MP; Kirk, DT; Kitto, A; Li, J; Li, M; Madden, E; Nichols, CM; Robinson, A; Sanchez, E; Swift, RA; Vescio, RA; Wang, CS; Waterman, GN; Yellin, O | 1 |
1 review(s) available for pyrazines and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
9 other study(ies) available for pyrazines and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
CSNK1α1 mediates malignant plasma cell survival.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2015 |
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Pseudo-Peritoneal Carcinomatosis Presentation of a Crystal-Storing Histiocytosis With an Unmutated Monoclonal κ Light Chain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallization; Histiocytosis; Humans; Immunoglobulin kappa-Chains; Kidney; Lymph Nodes; Macrophages; Male; Monoclonal Gammopathy of Undetermined Significance; Peritoneal Neoplasms; Pyrazines | 2015 |
Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Protease Inhibitors; Pyrazines; von Willebrand Diseases | 2010 |
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Transformation, Neoplastic; Gene Expression Profiling; Humans; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Mutation; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Survival Rate | 2011 |
Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fanconi Syndrome; Humans; Kidney; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Pyrazines; Renal Insufficiency, Chronic; Treatment Outcome | 2012 |
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Topics: Animals; B-Cell Maturation Antigen; Bone Marrow; Boronic Acids; Bortezomib; Cell Membrane; Culture Media, Conditioned; Cyclophosphamide; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunoglobulin G; Kaplan-Meier Estimate; Mice; Mice, SCID; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Plasma Cells; Pyrazines; Tumor Burden; Tumor Cells, Cultured | 2012 |